BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
The acquisition is centered around Biotheus’ main asset, BNT327/PM8002, which works by boosting the immune system to attack ...
BioNTech secured a leading candidate in the race one year ago by paying Biotheus $55 million upfront for the rights to PM8002 ...
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...
BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a Chinese biotechnology fir ...
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part ...
In particular, the drug candidate BNT327/PM8002 developed by Biotheus will be a key area of focus after the deal closes. Last year, BioNTech obtained the exclusive global development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback